CGChristian Geroin

Christian Geroin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian Geroin has a total of 446 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immersive Virtual Reality as a Probe of Context‐Dependent Gait Control: Reply to Peh et al

    by Marialuisa Gandolfi, Chiara Bonetto, Corrado Perin, Angela Sandri, Giulia Bonardi, Ilaria Antonella Di Vico, Laura Avanzino, Elisa Pelosin, Mauro Crestani, Christian Geroin, et al.

  • Open Access

    Multimodal assessment of clinical and neural changes following multidisciplinary management in functional motor disorders

    by Marialuisa Gandolfi, Angela Sandri, Elisabetta Sarasso, Andrea Gardoni, Michela Russo, Silvia Basaia, Ilaria Antonella Di Vico, Roberto Erro, Serena Camozzi, Giulia Pedrotti, et al.

    Functional motor disorders (FMD) are common and disabling conditions, but objective biomarker changes following multidisciplinary management remain limited. Our objective was to investigate changes and responsiveness of multimodal biomarkers in individuals with FMD undergoing multidisciplinary management. 34 patients with clinically definite FMD (mean age 42.76 ± 11.01 years; 85.7% female; mean disease duration 0.64 ± 1.52 years) underwent a standardized multimodal assessment at baseline and 3-month follow-up after a multidisciplinary program. The intervention included a 5-day intensive rehabilitation program (2 h/day), followed by a 12-week phase of telemedicine (one session every 2 weeks) and home-based self-management (two sessions/week). Multimodal biomarkers across motor, exteroceptive, interoceptive, and brain function domains were assessed using clinical, neurophysiological, and task-based functional MRI measures. Motor symptoms improved with concurrent gains in depressive symptoms, physical quality of life, and fatigue (all, p < 0.047). Specific improvements were observed in motor performance, including reduced stride time variability during cognitive dual-tasking ( p = 0.018) and enhanced postural stability mainly in the eyes-closed condition (all, p < 0.028), while neurophysiological and nociceptive measures remained unchanged. Patients showed altered baseline brain activity compared with controls; post-intervention changes were observed in motor, cerebellar, and fronto-insular regions ( p < 0.001, uncorrected), without correlations with clinical outcomes. Multidisciplinary management in FMD was associated with improved clinical outcomes and specific motor and neural changes, suggesting domain-specific responsiveness and a potential role for multimodal biomarkers, requiring confirmation in larger controlled studies. Trial Registration number NCT06328790. Registered on 26 March 2024.

  • Open Access

    Why Use Immersive Virtual Reality to Assess Gait in Functional Motor Disorders?

    by Marialuisa Gandolfi, Chiara Bonetto, Corrado Perin, Angela Sandri, Giulia Bonardi, Ilaria Antonella Di Vico, Laura Avanzino, Elisa Pelosin, Mauro Crestani, Christian Geroin, et al.

    Background: Functional motor disorders (FMD) are disabling conditions modulated by attentional demands. Immersive virtual reality (iVR) engages multiple attentional and sensory networks, but its application in people with FMD (PwFMD) remains limited. Objective: We investigated whether iVR modulates spatiotemporal gait parameters in PwFMD differently from people with Parkinson's disease (PwPD) and healthy controls (HC). Methods: Wearable insoles tracked spatiotemporal gait parameters in the PwFMD (n = 30), the PwPD (n = 32), and HCs (n = 42) across three real‐world (C1–C3) and three iVR (C4–C6) walking conditions with increasing cognitive and sensory load. Discriminative performance was evaluated using receiver operating characteristic (ROC) analysis, whereas group and condition effects were examined using repeated‐measures analysis of variance (ANOVA) adjusted for age, sex, and body mass index (BMI). The dual‐task effect (DTE) quantified the impact of cognitive load. Results: In the iVR condition (C4–C6), gait speed, stride length, and swing‐time variability discriminated both PwFMD and PwPD from the HCs with good accuracy (AUC > 0.8), particularly under higher dual‐task load (C5 and C6), whereas no parameter reliably differentiated the PwFMD from the PwPD using ROC analysis (AUC < 0.7). Adjusted ANOVA revealed significant group × condition interactions for multiple gait parameters ( P < 0.05). DTE analysis revealed distinct responses to cognitive load: dual‐task cost was greater in PwPD than in PwFMD, which was often comparable to the HCs, particularly under cognitive dual‐task conditions (C3 and C6). Conclusions: iVR revealed context‐dependent gait abnormalities and differential responses to cognitive load in PwFMD and PwPD, which suggests its use as a paradigm to probe underlying mechanisms. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Occupation and Education Level in Functional Motor Disorders

    by Tommaso Ercoli, Christian Geroin, Enrico Marcuzzo, Angela Sandri, Serena Camozzi, Luigi Michele Romito, Roberto Eleopra, Alessandra Nicoletti, Giovanni Mostile, Donatella Contrafatto, et al.

  • Open Access

    Pain in Functional Motor Disorders: Clinical Correlates From the Italian Registry

    by Veronica Nisticò, Benedetta Demartini, Christian Geroin, Enrico Marcuzzo, Angela Sandri, Luigi Michele Romito, Roberto Eleopra, Lucia Tesolin, Francesco de Bertoldi, Alessandra Nicoletti, et al.

    Background: Pain is a frequent and disabling symptom in patients with Functional Motor Disorders (FMD), yet its clinical correlates and impact have not been characterized in large, representative cohorts. The aims of this study were to identify clinical predictors and correlates of pain intensity and interference among FMD patients. Methods: We conducted a cross‐sectional analysis within the Italian Registry of Functional Motor Disorders, including 466 adults with FMD recruited from 25 movement disorders centers. Pain was assessed using the Brief Pain Inventory (BPI), which captures pain experienced during the 24 h prior to assessment, alongside sociodemographic, clinical, and psychometric data on depression, anxiety, alexithymia, fatigue, and quality of life. Results: Pain was reported by 78.8% of participants. Fibromyalgia strongly predicted pain, whereas comorbid epilepsy was linked to reduced risk. The presence of pain was associated with a poorer self‐reported sense of physical health. Among patients with pain, higher intensity and interference were associated with younger age, Restless Legs Syndrome, Irritable Bowel Syndrome, physical trauma as a precipitating factor for FMD, anxiety, and poorer physical and mental health. Painkillers were prescribed to 41.6% of patients, yet 39.27% reported pain despite medications, and 39.48% had pain while not receiving analgesics. Conclusions: Pain is highly prevalent in FMD when assessed over the previous 24 h and is frequently reported in patients who are either not receiving analgesics or continue to experience pain despite treatment. Multiple factors influence its intensity and interference in daily life. Longitudinal studies are needed to clarify causal relationships and to inform pain management strategies.

  • Open Access

    Identifying diagnostic biomarkers in functional motor disorders through multimodal behavioral, neurophysiological, and imaging assessment using explainable machine learning

    by Marialuisa Gandolfi, Angela Sandri, Michela Russo, Elisabetta Sarasso, Andrea Gardoni, Silvia Basaia, Roberto Erro, Sofia Cuoco, Immacolata Carotenuto, Carlo Ricciardi, et al.

    Functional motor disorders (FMDs) represent a frequent and disabling neurological condition. The lack of reliable diagnostic biomarkers and their heterogeneity might affect diagnosis. We identified multimodal biomarkers distinguishing FMDs from healthy controls (HCs) using machine-learning approaches. In this multicenter cross-sectional study, consecutive adults with a clinically established FMDs diagnosis (n = 75, 74.7% female; mean age 44.20 ± 12.92) and age- and sex-matched HCs (n = 75; 58.6% female; 48.42 ± 11.67) were recruited. All participants underwent standardized behavioral, neurophysiological, and brain MRI assessment exploring motor, exteroceptive, and interoceptive domains. A Random Forest (RF) classifier combined with repeated stratified k-fold cross-validation was trained on the collected features. Predictive performance was evaluated using accuracy, sensitivity, specificity, precision, F1-score, and AUC-ROC. SHapley Additive exPlanations interpreted feature importance. The strongest diagnostic biomarkers were lower dual-task effect scores for postural sway area under eyes-closed motor and cognitive conditions, and gait speed during the motor dual-task, followed by increased vDMN and basal ganglia networks functional connectivity, reduced baseline ipsilateral-contralateral R2 blink reflex area, and higher DNIC-to-baseline N2P2 amplitude ratios for the lower limb. The RF classifier achieved robust performance (accuracy 85.0%, sensitivity 83.9%, specificity 86.1%, F1-score 85.7%, AUC-ROC 0.921). Motor, functional neuroimaging, and neurophysiological markers demonstrated diagnostic value in distinguishing FMDs from healthy controls, addressing the current lack of objective tools and supporting more confident and accurate diagnosis of these heterogeneous conditions. Trial registration number NCT06328790. Registered on 26 March 2024.


  • Open Access

    Clinical features of adolescent-onset functional motor disorders in tertiary movement disorders centers

    by Christian Geroin, Tommaso Ercoli, Enrico Marcuzzo, Angela Sandri, Serena Camozzi, Domenico Maddaloni, Luigi Michele Romito, Roberto Eleopra, Lucia Tesolin, Serena Pellegrin, et al.

    Background: Functional Motor Disorders (FMDs) represent a diagnostic and therapeutic challenge in pediatric neurology, particularly among adolescents. Their clinical presentation is common but often nonspecific, leading to frequent misdiagnoses and diagnostic delays. We aimed to characterize FMDs in adolescents and to examine the frequency of isolated and combined phenotypes and their associations with demographic and clinical variables. Methods: In this observational study, data were obtained from the Italian Registry of FMDs, including patients with a clinically definite diagnosis of FMD consecutively enrolled at 25 Italian tertiary movement disorders centers. Results: Among 847 patients, 93 (10.9%) had adolescent-onset FMDs. Motor phenotypes did not differ significantly between adolescent- and adult-onset FMDs, with the exception of parkinsonism, which was observed only in the latter. Compared with adult-onset FMDs, adolescent-onset FMDs were associated with a longer disease duration, a higher number of medical consultations before diagnosis, and a higher frequency of functional seizures and infections, but with lower rates of insomnia, fatigue, and antipsychotic use. In multivariable analysis, adolescent-onset FMDs remained independently associated with a greater number of medical consultations (adjusted OR 1.07; 95% CI 1.02–1.13), the presence of functional seizures (adjusted OR 2.06; 95% CI 1.09–3.8), and with lower occurrence of insomnia (adjusted OR 0.49; 95% CI 0.27–0.92) and fatigue (adjusted OR 0.51; 95% CI 0.30–0.86). Pain was more likely to be associated with the combined FMDs phenotype. Conclusions: Adolescent-onset FMDs are common and are associated with several non-motor symptoms in tertiary movement disorders centers . Early and accurate diagnosis may help to reduce unnecessary investigations and inappropriate treatments.

  • Open Access

    Enhanced recovery after surgery for gastric cancer with HIPEC: feasibility and outcomes in a complex setting

    by Francesco Casella, Christian Geroin, Francesca Meloni, Maria Bencivenga, Eugenia Mattioni, Serena Camozzi, Jacopo Weindelmayer

  • Open Access

    Clinical Algorithm‐Guided Approach to Botulinum Toxin Type A Treatment for Axial Postural Abnormalities in Parkinson's Disease

    by Giacomo Argenziano, Giovanna Squintani, Serena Camozzi, Ilaria Di Vico, Marialuisa Gandolfi, Carlo Alberto Artusi, Michele Tinazzi, Christian Geroin

    Background: Axial postural abnormalities (APAs) are common, disabling complications of Parkinson's disease (PD) with unclear pathophysiology. The presence of hyperactivity in multiple trunk muscles supports the use of botulinum toxin (BTA). However, its application is complex, due to the lack of standardized clinical and electrophysiological approach. Objectives: To evaluate BTA injections effectiveness using a clinical algorithm that integrates trunk angle severity and electromyography (EMG)‐detected muscle hyperactivity in patients with APAs. Methods: This is prospective, open‐label, pilot study. A novel decisional algorithm guided muscle selection, based on the bending degree and EMG findings. PD patients with different APAs underwent trunk angle measurement and EMG polygraphy of axial muscles in the standing position and during trunk activation. Primary outcome was the change in trunk misalignment measured before and one month after BTA injection. Secondary outcomes were the Clinical Global Impression of Change‐Improvement (CGI‐pain and CGI‐posture) and the Numeric Rating Scale (NRS) for pain. Results: Among 52 PD patients, 20(38.5%) were eligible for treatment. At one‐month follow‐up, lateral trunk flexion (LTF) improved [LTF angle from 11.5 (CI 7.1–15.9) to 9.9, (CI 5.2–14.7) P = 0.013], while anterior trunk flexion (ATF) did not (thoracic fulcrum ATF from 41.4 to 40.6, P > 0.05; lumbar fulcrum ATF from 25.7 to 24.5, P > 0.05). CGI‐posture improved in 45% of cases, CGI‐pain improved in 50% of cases, and NRS decreased from 6.3 to 4.8 ( P = 0.010). Conclusions: A clinical and neurophysiological algorithm integrating measures of trunk bending and EMG‐detected muscle hyperactivity can optimize BTA treatment for APAs in PD, improving motor/ non‐motor outcomes.


  • Open Access

    The Complex Pathway of Conventional Investigations before the Diagnosis of Functional Motor Disorders

    by Tommaso Ercoli, Christian Geroin, Enrico Marcuzzo, Angela Sandri, Luigi Michele Romito, Roberto Eleopra, Lucia Tesolin, Francesco de Bertoldi, Alessandra Nicoletti, Giovanni Mostile, et al.

    Background: Functional motor disorder (FMD) is a diagnosis of inclusion based on the presence of positive signs on clinical examination, and only a few tests are validated as biomarkers for FMD identification. Objectives: The aim of this study was to assess the relative frequency of different types of conventional instrumental investigations (such as magnetic resonance imaging/computed tomography [MRI/CT] scan, dopamine transporter single‐photon emission computed tomography (DaT‐SPECT), electroencephalography (EEG), neurophysiological tests, and other tests) in FMD patients before diagnosis and to identify the clinical and demographic features associated with their use. Methods: Data were obtained from the Italian Registry of Functional Motor Disorders, a multicenter initiative involving patients with a diagnosis of clinically definite FMD. Patients were consecutively enrolled at 25 Italian centers during 2 phases. Data collection initially took place between September 2018 and August 2019, and during phase 2, between January 2020 and December 2022. Results: Among the 853 patients included during the 2 phases of the registry, we identified 794 patients (93.1%) who underwent 1 or more categories of conventional investigations. Overall, conventional investigations were more likely to be performed in older FMD patients (Odds ratio [OR]: 1.02; P = 0.013). Interestingly, we found that more than one category of investigation was more likely to be performed in FMD patients presenting with weakness (OR: 1.85; P = 0.002) and with additional functional symptoms (OR: 1.54; P = 0.026). Conclusions: Our findings provide novel insights into the complex diagnostic process of FMD patients. This study highlights the need to identify reliable biomarkers that may help physicians diagnose FMD earlier and carefully select the most appropriate conventional investigations.